Introduction
============

Autism is a life-long neurodevelopmental condition interfering with the person\'s ability to communicate and relate to others. Since the earliest epidemiological surveys in the 1960s, a wealth of data has become available, indicating a much higher prevalence of the condition than previously thought \[Fombonne, [@b29], [@b31]; Fombonne, Quirke, & Hagen, [@b32]\]. It is now recognized that some individuals with the condition are able to lead independent and fulfilling lives, whereas for others the impact can be severe, interfering significantly with quality of life \[Farley et al., [@b28]\]. While the global burden of autism is currently unknown, in the United States and in the UK, the annual societal cost of the condition exceeds several billions \[Ganz, [@b35]; Knapp, Romeo, & Beecham, [@b53]\].

Increased recognition, understanding, and awareness of autism in the last few decades have been, in part, driven by the significant growth in research evidence. While many aspects of autism remain poorly understood, major advances have been made in terms of highlighting the genetic \[Abrahams & Geschwind, [@b1]\], biological \[Belmonte et al., [@b13]\], environmental \[Currenti, [@b24]\], and developmental \[Elsabbagh & Johnson, [@b27]\] origins of the condition. Large-scale and well controlled cohort studies (e.g., <http://www.earlistudy.org>) following-up pregnant mothers are likely to clarify the effects of some pre- and perinatal risk factors implicated in autism. Significant strides have also contributed towards developing and validating screening and diagnostic instruments, helping to reduce heterogeneity in clinical characterization in research studies. While some of these diagnostic tools remain highly resource intensive, they are increasingly used in clinical settings, as they provide rich and systematic information to inform service provisions where those are available. However, even in high-income countries, provisions for screening, diagnosis, and intervention are highly variable and many cases absent in community settings.

Such advances in autism research have contributed towards bridging the gap between evidence and practice in some countries, but there is little systematic information available with regards to the impact of the condition on most of the world\'s population. Frequently regarded as essential for advancing basic research and strategic for informing policy and developing services, epidemiological studies have emerged as a clear priority within several global initiatives. The charity Autism Speaks in partnership with the US Center for Disease Control (CDC) launched the International Autism Epidemiology Network (<http://www.autismepidemiology.net>), bringing together researchers worldwide and focusing specifically on service improvements in developing countries. According to the network, prevalence studies for PDD are ongoing in Australia, Mexico, Finland, Portugal, Iceland, India, Vietnam, Taiwan, South Africa, and Uganda. Focusing on a broader context than autism, the Movement for Global Mental Health has identified a clear treatment gap, particularly pronounced in low- and middle-income countries \[<http://www.globalmentalhealth.org>; Patel et al., [@b68]\]. Epidemiological data on the burden of mental and neurological disorders and systematic mapping of relevant services in low- and middle-income countries encouraged World Health Organization (WHO) to launch the mental health Gap Action Programme (mhGAP) \[WHO, [@b84]\]. Moreover, the Global Alliance for Chronic Disease, which groups several agencies including Australia\'s National Health Medical Research Council, the Canadian Institutes of Health Research, the Chinese Academy of Medical Science, the UK\'s Medical Research Council, and the United States\' National Institutes of Health, announced a program to identify the world\'s "Grand Challenges in Global Mental Health" (<http://www.grandchallenges.org>). The reasons for why epidemiological surveys are viewed as a priority extend beyond the need for objective and robust estimates of prevalence. These provide additional valuable benefits as they often result in systematic information regarding existing services and may help in assessing the needs and priorities for each community. In the long run, the availability of comparable estimates from different geographic regions may also enable testing challenging hypotheses regarding the etiology of PDD.

Systematic Review Methodology
=============================

The primary aim of this report is to provide an up-to-date and systematic review of the methodological features and substantive results of epidemiological surveys of the prevalence of pervasive developmental disorders (PDDs), including autistic disorder (AD) worldwide. This is to our knowledge the first attempt to review available evidence from different world regions, including low- and middle-income countries. While the scope of the current review does not provide extensive coverage of the situation in all countries, every effort was made to represent objectively available evidence from regions where research capacity is limited.

Search Strategies
-----------------

We adopted a systematic review methodology in the identification of epidemiological reports included in the current article. First, as a preliminary step, key findings from previous reviews of epidemiological surveys were incorporated into the current report \[Fombonne, [@b29], [@b31]; Fombonne et al., [@b32]; Sun & Allison, [@b79]; Williams, Higgins, & Brayne, [@b86]\]. Second, several authors or group of authors undertook a comprehensive review of available evidence from regions that were underrepresented in previous reviews. Different countries were grouped into subregions according to the WHO classification. The main search strategy was to perform extensive region and/or country-specific search of Medline publications. When the authors were familiar with additional local or regional search engines, these were also used. Additional search sources included IndMed search engine, indmed.nic.in national medical database, VIP.cn Chinese search engine, and <http://arabpsynet.com> regional engine. Search terms included Autis\*, Asperger, Autistic Disorder and Child Development and Disorders, Pervasive (mesh term), or their other-language equivalent. In regions where it was difficult to identify epidemiological reports, authors also consulted other researchers and practitioners who supplied references or information. Using these strategies authors identified and reviewed over 600 studies typically not included in previous reviews (133 from South and Central America, and the Caribbean, 319 from South East Asia and the Western Pacific, and 130 from the Eastern Mediterranean, 54 from Africa). Languages of the identified articles included Arabic, Chinese, Dutch, English, French, Portuguese, and Spanish.

Inclusion and Exclusion Criteria of Prevalence Estimate
-------------------------------------------------------

From the identified publications, the following criteria were used for selecting epidemiological surveys included in [Tables I](#tblI){ref-type="table"}--[III](#tblIII){ref-type="table"}:

-   A full article (published or otherwise) was available in a language that could be read by one of the authors.

-   The primary aim of the survey was to estimate prevalence of PDD and/or narrower AD. Studies exclusively focusing on other categories of PDD, including childhood disintegrative disorder and Asperger disorder (see details in the following) were excluded from the current review as these were very rare and have been reviewed elsewhere \[Fombonne et al., [@b32]\]. Other articles, including a wealth of case reports, surveys of more general intellectual or mental disabilities, and surveys estimating PDD prevalence among comorbid conditions, were also excluded from the current report.

-   The survey included a step of diagnostic confirmation regardless of the specific approach taken to verify caseness (see following discussion for further details). Those studies providing prevalence estimates without diagnostic confirmation, particularly from regions where the evidence base is overall limited, were reviewed in the following main text but are not presented in the tables.

-   The following information categories were included or could be ascertained based on information from the survey: the country and area where the survey was conducted, the size of the population based on which the prevalence estimate was ascertained, the age range of the participants, the number affected by AD or PDD, the diagnostic criteria used in case ascertainment, gender ratio within the affected sample, prevalence estimate (number per 10 000), and 95% confidence intervals (CI) for the estimate.

[Tables I](#tblI){ref-type="table"}--[III](#tblIII){ref-type="table"} summarize the results of epidemiological surveys identified in different world regions. Studies estimating either AD or PDD as a spectrum of disorders from each region were grouped and ordered by publication year. Characteristics of samples surveyed in these studies are briefly summarized. A secondary aim of this report was to review evidence for the possible impact of geographic, economic, social, or cultural/ethnic factors on the clinical presentation and the prevalence of PDD. To that end, selected studies relevant for clinical presentation, particularly from underrepresented regions were reviewed. This included information on gender differences in the rates of PDD, cognitive characteristics of the identified cases, medical history, or socioeconomic and ethnic characteristics.

###### 

Europe

  Region   Category   Year   Authors                     Country    Area                              Population   Age        Number affected                       Diagnostic criteria                                \% with average IQ                     Gender ratio    Prevalence/ 10 000                       95% CI
  -------- ---------- ------ --------------------------- ---------- --------------------------------- ------------ ---------- ------------------------------------- -------------------------------------------------- -------------------------------------- --------------- ---------------------------------------- -----------------------------------------
  Europe   AD         1966   Lotter                      UK         Middlesex                         78 000       8--10      32                                    Rating scale                                       15.6                                   2.6 (23/9)      4.1                                      2.7; 5.5
           AD         1972   Brask                       Denmark    Aarhus County                     46 500       2--14      20                                    Clinical                                           ---                                    1.4 (12/7)      4.3                                      2.4; 6.2
           AD         1976   Wing et al.                 UK         Camberwell                        25 000       5--14      17[a](#tfI-1){ref-type="table-fn"}    24-item rating scale of Lotter                     30                                     16 (16/1)       4.8[b](#tfI-2){ref-type="table-fn"}      2.1; 7.5
           AD         1983   Bohman et al.               Sweden     County of Västerbotten            69 000       0--20      39                                    Rutter criteria                                    20.5                                   1.6 (24/15)     5.6                                      3.9; 7.4
           AD         1984   McCarthy et al.             Ireland    East                              65 000       8--10      28                                    Kanner                                             ---                                    1.33 (16/12)    4.3                                      2.7; 5.9
           AD         1986   Steinhausen et al.          Germany    West Berlin                       279 616      0--14      52                                    Rutter                                             55.8                                   2.25 (36/16)    1.9                                      1.4; 2.4
           AD         1989   Cialdella and Mamelle       France     Rhône                             135 180      3--9       61                                    DSM-III like                                       ---                                    2.3             4.5                                      3.4; 5.6
           AD         1991   Gillberg et al.             Sweden     South-West Gothenburg, Bohuslän   78 106       4--13      74                                    DSM-III-R                                          18                                     2.7 (54/20)     9.5                                      7.3; 11.6
           AD         1992   Fombonne and du Mazaubrun   France     4 regions                         274 816      9 & 13     154                                   Clinical-ICD-10 like                               13.3                                   2.1 (105/49)    4.9                                      4.1; 5.7
           AD         1997   Fombonne et al.             France     3 regions                         325 347      8--16      174                                   Clinical ICD-10-like                               12.1                                   1.81 (112/62)   5.35                                     4.6; 6.1
           AD         1997   [@b81]                      UK         South Glamorgan, Wales            73 301       3--15      53                                    DSM-III-R                                          ---                                    6.57 (46/7)     7.2                                      5.3; 9.3
           AD         1997   [@b9]                       Sweden     Mölnlycke                         1 941        3--6       9                                     ICD-10                                             22.2                                   3.5 (7/2)       46.4                                     16.1; 76.6
           AD         1998   Sponheim & Skjeldal         Norway     Akershus County                   65 688       3--14      34                                    ICD-10                                             47.1[c](#tfI-3){ref-type="table-fn"}   2.09 (23/11)    5.2                                      3.4; 6.9
           AD         1999   Taylor et al.               UK         North Thames                      490 000      0--16      427                                   ICD-10                                             ---                                    ---             8.7                                      7.9; 9.5
           AD         1999   Kadesjö et al.              Sweden     Karlstad                          826          6.7--7.7   6                                     DSM-III-R/ICD-10 Gillberg criteria for AS          50.0                                   5.0 (5/1)       72.6                                     14.7; 130.6
           AD         2000   Baird et al.                UK         South-East Thames                 16 235       7          50                                    ICD-10                                             60                                     15.7 (47/3)     30.8                                     22.9; 40.6
           AD         2000   [@b72]                      UK         West Midlands                     25 377       1--5       62                                    Clinical/ICD10/DSM-IV                              ---                                    ---             7.8                                      5.8; 10.5
           AD         2000   [@b50]                      Finland    North (Oulu et Lapland)           27 572       5--7       57                                    DSM-IV                                             49.8[d](#tfI-4){ref-type="table-fn"}   4.12 (156/50)   20.7                                     15.3; 26.0
           AD         2001   Davidovitch et al.          Israel     Haifa                             26 160       7--11      26                                    DSM-III-R/DSM-IV                                   ---                                    4.2 (21/5)      10.0                                     6.6; 14.4
           AD         2007   Oliveira et al.             Portugal   Mainland and Azores               67 795       6--9       115                                   DSM-IV                                             17                                     2.9             16.7                                     14.0; 20.0
           AD         2001   Fombonne et al.             UK         England and Wales                 10 438       5--15      27                                    DSM-IV/ICD-10                                      55.5                                   8.0 (24/3)      26.1                                     16.2; 36.0
           AD         2001   [@b61]                      Iceland    Whole Island                      43 153       5--14      57                                    Mostly ICD-10                                      15.8                                   4.2 (46/11)     13.2                                     9.8; 16.6
           AD         2001   [@b21]                      UK         Stafford                          15 500       2.5--6.5   26                                    ICD10/DSM-IV                                       29.2                                   3.3 (20/6)      16.8                                     10.3; 23.2
           AD         2002   Madsen et al.               Denmark    National register                 63 859       8          46                                    ICD-10                                             ---                                    ---             7.2                                      5.0--10.0
           AD         2004   Tebruegge et al.            UK         Kent                              2 536        8--9       6                                     ICD-10                                             ---                                    (6/0)           23.7                                     9.6; 49.1
           AD         2005   Chakrabarti & Fombonne      UK         Stafford                          10 903       4--7       24                                    ICD-10/DSM-IV                                      33.3                                   3.8 (19/5)      22.0                                     14.4; 32.2
           AD         2006   Gillberg et al.             Sweden     Göteborg                          32 568       7--12      115                                   Gillberg\'s criteria                               ---                                    3.6 (90/25)     35.3                                     29.2; 42.2
           AD         2006   Baird et al.                UK         London (South Thames)             56 946       9--10      81                                    ICD-10                                             47                                     8.3 (≍ 72/9)    38.9                                     29.9; 47.8
           AD         2007   Ellefsen et al.             Denmark    Faroe Islands                     7 689        8--17      12                                    ICD-10 Gillberg criteria for AS                    ---                                    3.0 (9/3)       16.0                                     7.0; 25.0
           AD         2007   Latif and Williams          UK         Wales                             39 220       0--17      50                                    Kanner                                             ---                                    ---             12.7                                     9.0; 17.0
           AD         2008   Williams et al.             UK         South West (Avon)                 14 062       11         30                                    ICD-10                                             86.7                                   5.0 (25/5)      21.6                                     13.9; 29.3
           PDD        2000   Baird et al.                UK         London (South Thames)             16 235       7          94                                    ICD-10                                             60                                     15.7 (83/11)    57.9                                     46.8; 70.9
           PDD        2001   Chakrabarti and Fombonne    UK         Stafford                          15 500       4--7       96                                    ICD-10                                             74.2                                   3.8 (77/20)     61.9                                     50.2; 75.6
           PDD        2002   Madsen et al.               Denmark    National register                 ---          8          738                                   ICD-10                                             ---                                    ---             30.0                                     ---
           PDD        2002   Scott et al.                UK         Cambridge                         33 598       5--11      196                                   ICD-10                                             ---                                    4.0 (---)       58.3 [\*](#tfI-7){ref-type="table-fn"}   50; 67[\*](#tfI-7){ref-type="table-fn"}
           PDD        2004   Tebruegge et al.            UK         Kent                              2 536        8--9       21                                    ICD-10                                             ---                                    6.0 (18/3)      82.8                                     51.3; 126.3
           PDD        2005   Chakrabarti and Fombonne    UK         Stafford                          10 903       4--6       64                                    ICD-10                                             70.2                                   6.1 (55/9)      58.7                                     45.2; 74.9
           PDD        2006   Baird et al.                UK         South Thames                      56 946       9--10      158                                   ICD-10                                             45                                     3.3 (121/37)    116.1                                    90.4; 141.8
           PDD        2006   Harrison et al.             UK         Scotland                          134 661      0--15      443[e](#tfI-5){ref-type="table-fn"}   ICD-10, DSMIV                                      ---                                    7.0 (369/53)    44.2                                     39.5; 48.9
           PDD        2006   Gillberg et al.             Sweden     Göteborg                          32 568       712        262                                   DSM-IV                                             ---                                    3.6 (205/57)    80.4                                     71.3; 90.3
           PDD        2007   Latif and Williams          UK         South Wales                       39 220       0--17      240                                   ICD-10, DSM-IV, Kanner\'s & Gillberg\'s criteria   ---                                    6.8 ---         61.2                                     54; 69[\*](#tfI-7){ref-type="table-fn"}
           PDD        2007   Ellefsen et al.             Denmark    Faroe Islands                     7 689        8--17      41                                    DSM-IV, Gillberg\'s criteria                       68.3                                   5.8 (35/6)      53.3                                     36; 70
           PDD        2008   Williams et al.             UK         Avon                              14 062       11         86                                    ICD-10                                             85.3                                   6.8 (75/11)     61.9                                     48.8; 74.9
           PDD        2009   Baron---Cohen et al.        UK         Cambridge                         8 824        5--9       83                                    ICD-10                                             ---                                    ---             94[f](#tfI-6){ref-type="table-fn"}       75; 116
           PDD        2011   Brugha et al.               UK         National                          7 333        \>16       72                                    ADOS-4                                             100%                                   3.8 ---         98                                       30; 165

Calculated by the author.

This number corresponds to the sample described in Wing and Gould \[[@b89]\].

This rate corresponds to the first published paper on this survey and is based on 12 participants amongst children aged 5 to 14 years.

In this study, mild mental retardation was combined with average IQ, whereas moderate and severe mental retardation were grouped together.

These figures apply to the whole study sample of 206 participants with an autism spectrum disorder (ASD).

Estimated using a capture-recapture analysis, the number of cases used to calculate prevalence was estimated to be 596.

Rate based on Special Education Needs register. A figure of 99/10 000 is provided from a parental and diagnostic survey. Other estimates in this study vary from 47 to 165/10 000 deriving from various assumptions made by the authors.

AD, autistic disorder; AS, Asperger syndrome; DSM, Diagnostic and Statistical Manual of Mental Disorders; ICD, International Classification of Diseases. PDD, developmental disorder.

###### 

Western Pacific, South East Asia, and the Eastern Mediterranean

  Region                    Category   Year   Authors                                   Country       Area               Population                                  Age      Number affected   Diagnostic criteria         \% with average IQ   Gender ratio    Prevalence/ 10 000                     95% CI
  ------------------------- ---------- ------ ----------------------------------------- ------------- ------------------ ------------------------------------------- -------- ----------------- --------------------------- -------------------- --------------- -------------------------------------- ------------------------------------------------
  Western Pacific           AD         1982   Hoshino et al.                            Japan         Fukushima-Ken      609 848                                     0--18    142               Kanner\'s criteria          ---                  9.9 (129/13)    2.33                                   1.9; 2.7
                            AD         1987   Matsuishi et al.                          Japan         Kurume City        32 834                                      4--12    51                DSM-III                     ---                  4.7 (42/9)      15.5                                   11.3; 19.8
                            AD         1988   Tanoue et al.                             Japan         Southern Ibaraki   95 394                                      7        132               DSM-III                     ---                  4.07 (106/26)   13.8                                   11.5; 16.2
                            AD         1989   Sugiyama et Abe                           Japan         Nagoya             12 263                                      3        16                DSM-III                     ---                  ---             13.0                                   6.7; 19.4
                            AD         1996   [@b42]                                    Japan         Yokohama           8 537                                       5        18                ICD-10                      50.0                 2.6 (13.5)      21.08                                  11.4; 30.8
                            AD         2000   Luo                                       China         Fujian             10 802                                      0--14    3                 ABC, CCMD-2-R & DSM-III-R   ---                  2:1             2.8                                    0.6; 8.1[\*](#tfII-1){ref-type="table-fn"}
                            AD         2002   Wang et al.                               China         JiangSu            3 912                                       2--6     7                 CABS, CARS,CCMD2-R          ---                  2.5:1           17.9                                   7.2; 36.8[\*](#tfII-1){ref-type="table-fn"}
                            AD         2003   Wang et al.                               China         JiangSu            7 344                                       2--6     9                 CABS, CARS, CCMD2-R,        ---                  2:1             12.3                                   5.6; 23.3[\*](#tfII-1){ref-type="table-fn"}
                            AD         2004   Guo et al.                                China         Tianjin            3 606                                       2--6     5                 CARS,CCMD-2-R,CABS          ---                  All boys        13.9                                   4.5; 32.3[\*](#tfII-1){ref-type="table-fn"}
                            AD         2004   Zhang et al.                              China         Tianjin            7 316                                       2--6     8                 CARS, DSM--IV               0                    (7:1)           10.9                                   4.7; 21.5[\*](#tfII-1){ref-type="table-fn"}
                            AD         2005   Zhang & Ji                                China         Tianjin            7 345                                       2--6     8                 DSM-IV, CARS                ---                  7               10.9                                   4.7; 21.4[\*](#tfII-1){ref-type="table-fn"}
                            AD         2005   [@b43][a](#tfII-2){ref-type="table-fn"}   Japan         Yokohama           32 791                                      5        123               ICD-10                      25.3                 2.5 (70/27)     37.5                                   31.0; 45.0
                            AD         2007   Yang et al.                               China         Zunyi city         10 412                                      3--12    6                 DSM-IV, ABC                 ---                  (5/1)           5.8                                    2.1; 12.5[\*](#tfII-1){ref-type="table-fn"}
                            AD         2007   Chen et al.                               China         Taiwan             329 539                                     3--8     1115              ICD-10                      ---                  4.13            34[\*](#tfII-1){ref-type="table-fn"}   32; 36[\*](#tfII-1){ref-type="table-fn"}
                            AD         2008   Zhang et al.                              China         Wuxi city          25 521                                      1--6     25                CARS/DSM-IV                 ---                  3.2             9.8                                    6.3; 14.5[\*](#tfII-1){ref-type="table-fn"}
                            AD         2009   Zhang et al.                              China         GuiZhou            5 000                                       1--6     5                 CCMD-2-R, CARS, CABS        ---                  4:1             10.0                                   3.2; 23.3[\*](#tfII-1){ref-type="table-fn"}
                            AD         2011   Kim et al.                                South Korea   Goyang             55 266                                      7--12    27                DSM-IV                      55.6                 4.4             94                                     56; 134
                            PDD        2004   Icasiano et al.                           Australia     Barwon             45 153 [\*](#tfII-1){ref-type="table-fn"}   2--17    177               DSM-IV                      53.4                 8.3 (158/19)    39.2                                   34; 45[\*](#tfII-1){ref-type="table-fn"}
                            PDD        2008   Wong and Hui                              China         Hong Kong          4 247 206                                   0--14    682               DSM-IV                      30                   6.6 (592/90)    16.1                                   14.9; 17.3[\*](#tfII-1){ref-type="table-fn"}
                            PDD        2008   Kawamura et al.                           Japan         Toyota             12 589                                      5--8     228               DSM-IV                      66.4                 2.8 (168/60)    181.1                                  158.5; 205.9[\*](#tfII-1){ref-type="table-fn"}
                            PDD        2011   Kim et al.                                South Korea   Goyang             55 266                                      7--12    104               DSM-IV                      72                   2.4             189                                    143; 236
  South East Asia           AD         1992   Wignyo-sumarto et al.                     Indo-nesia    Yogyakarita        5 120                                       4--7     6                 CARS                        0                    2.0 (4/2)       11.7                                   2.3; 21.1
                            PDD        2009   Perera et al.                             Sri Lanka     Semi urban area    374                                         1.5--2   4                 DSM-IV, Parent report       ---                  All boys        107                                    2.9.2; 271.6[\*](#tfII-1){ref-type="table-fn"}
  Eastern Medi- terranean   PDD        2007   Eapen et al.                              UAE           Three regions      694                                         3.5      2                 DSM-IV                      ---                  5.14 (---)      29                                     3.5; 103.7[\*](#tfII-1){ref-type="table-fn"}
                            PDD        2010   Al-Farsi et al.                           Oman          Country-wide       798 913                                     0--14    113               DSM-IV                      ---                  2.9 (84/29)     1.4                                    1.2; 1.7
                            PDD        2012   Samadi et al.                             Iran          Country-wide       1 320 334                                   5        826               ADI-R                       ---                  4.3             6.26                                   5.84; 6.70

Calculated by the author

This figure was calculated by the author and refers to prevalence data (not cumulative incidence) presented in the paper (the M/F ratio is based on a subsample).

AD, autistic disorder; ADI-R, Autism Diagnostic Interview-Revised; CARS, Childhood Autism Rating Scale; CABS, Clancy Autism Behavior Scale; CCMD, Chinese Classification of Mental Disorders; DSM, Diagnostic and Statistical Manual of Mental Disorders; ICD, International Classification of Diseases. PDD, developmental disorder.

###### 

America

  Region                      Category   Year    Authors                  Country      Area                                               Population   Age     Number affected   Diagnostic criteria      \% with average IQ                           Gender ratio       Prevalence/ 10 000                              95% CI
  --------------------------- ---------- ------- ------------------------ ------------ -------------------------------------------------- ------------ ------- ----------------- ------------------------ -------------------------------------------- ------------------ ----------------------------------------------- -----------------------------------------------
  America                     AD         1970    Treffert                 USA          Wisconsin                                          899 750      3--12   69                Kanner                   ---                                          3.06 (52/17)       0.7                                             0.6; 0.9
                              AD         1987    Burd et al.              USA          North Dakota                                       180 986      2--18   59                DSM-III                  ---                                          2.7 (43/16)        3.26                                            2.4; 4.1
                              AD         1988    Bryson et al.            Canada       Part of Nova-Scotia                                20 800       6--14   21                New RDC                  23.8                                         2.5 (15/6)         10.1                                            5.8; 14.4
                              AD         1989    Ritvo et al.             USA          Utah                                               769 620      3--27   241               DSM-III                  34                                           3.73 (190/51)      2.47                                            2.1; 2.8
                              AD         2001    Bertrand et al.          USA          Brick Township, New Jersey                         8 896        3--10   36                DSM-IV                   36.7                                         2.2 (25/11)        40.5                                            28.0; 56.0
                              AD         2002    Croen et al.             USA          California DDS                                     4 950 333    5--12   5 038             CDER « Full syndrome »   62.8[a](#tfIII-1){ref-type="table-fn"}       4.47 (4116 /921)   11.0                                            10.7; 11.3
                              AD         2005    Barbaresi et al          USA          Minnesota (Olmstead County)                        37 726       0--21   112               DSM-IV                   ---                                          ---                29.7                                            24.0; 36.0
                              AD         2006    Fombonne et al.          Canada       Montreal island                                    27 749       5--17   60                DSM-IV                   ---                                          5.7 (51/9)         21.6                                            16.5; 27.8
                              AD         2008    Montiel-Nava et al.      Venez-uela   Maracaibo                                          254 905      3--9    430               DSM-IV-TR                ---                                          3:1                17                                              15; 19[\*](#tfIII-7){ref-type="table-fn"}
                              AD         2009    van Balkom et al.        Aruba        National                                           13 109       0--13   25                DSM-IV                   36.0                                         7.3 (22/3)         19.1                                            12.3; 28.1
                              AD         2010    Lazoff et al.            Canada       Montreal                                           23 635       5--17   68                DSM-IV                   ---                                          5.8 (58/10)        25.4                                            19.0; 31.8
                              PDD        2001    Bertrand et al.          USA          New Jersey                                         8 896        3--10   60                DSM-IV                   51                                           2.7 (44/16)        67.4                                            51.5; 86.7[\*](#tfIII-7){ref-type="table-fn"}
                              PDD        2003    Yeargin-Allsopp et al.   USA          Atlanta                                            289 456      3--10   987               DSM-IV                   31.8                                         4.0 (787/197)      34.0                                            32; 36
                              PDD        2003    Gurney et al.            USA          Minnesota                                          ---          8--10   ---               ---                      ---                                          ---                52.0 - 66.0[b](#tfIII-2){ref-type="table-fn"}   --- ---
                              PDD        2006    Fombonne et al.          Canada       Montreal                                           27 749       5--17   180               DSM-IV                   ---                                          4.8 (149/31)       64.9                                            55.8; 75.0
                              PDD        2007a   CDC                      USA          6 states                                           187 761      8       1 252             DSM-IV-TR                38 to 60[c](#tfIII-3){ref-type="table-fn"}   2.8 to 5.5         67.0                                            ---[d](#tfIII-4){ref-type="table-fn"}
                              PDD        2007b   CDC                      USA          14 states                                          407 578      8       2 685             DSM-IV-TR                55.4[e](#tfIII-5){ref-type="table-fn"}       3.4 to 6.5         66.0                                            63; 68
                              PDD        2008    Nicholas et al.          USA          South Carolina[f](#tfIII-6){ref-type="table-fn"}   47 726       8       295               DSM-IV-TR                39.6                                         3.1 (224/71)       62.0                                            56; 70
                              PDD        2009    Kogan et al.             USA          Nationwide                                         77 911       3--17   913               ---                      ---                                          4.5 (746/167)      110                                             94; 128
                              PDD        2009    CDC                      USA          11 states                                          3307 790     8       2 757             DSM-IV                   59                                           4.5 (---)          89.6                                            86; 93
                              PDD        2010    Lazoff et al.            Canada       Montreal                                           23 635       5--17   187               DSM-IV                   ---                                          5.4 (158/29)       79.1                                            67.8; 90.4
  South America & Caribbean   PDD        2008    Lejarraga et al.         Argentina    San Isidro                                         839          0--5    11                DSM-IV                   ---                                          ---                13.1                                            7.3; 23.6[\*](#tfIII-7){ref-type="table-fn"}
                              PDD        2009    Van Balkom et al.        Aruba        National                                           13 109       0--13   69                DSM-IV                   58.8                                         6.7 (60/9)         52.6                                            41.0; 66.6
                              PDD        2010    Paula et al.             Brazil       Atibaia                                            1 470        7--12   4                 DSM-IV                   ---                                          (4/0)              27.2                                            17.6; 36.8

calculated by the author.

This proportion is likely to be overestimated and to reflect an underreporting of mental retardation in the CDER evaluations.

These are the highest prevalence estimated reported in this study of time trends. The prevalence in 10-year olds is for the 1991 birth cohort, and that for 8-year olds for the 1993 birth cohort. Both prevalences were calculated in the 2001--2002 school year.

Specific values for % with average IQ are available for each state prevalence.

Confidence intervals are available for each state prevalence.

Average across seven states.

Children aged 8, born either in 2000 and 2002, and included in the two CDC multisite reports.

AD, autistic disorder; CDER, California Department of Disabilities; DSM, Diagnostic and Statistical Manual of Mental Disorders; PDD, developmental disorder; RDC, Research Diagnostic Criteria.

Combining and Appraising Results
--------------------------------

Each group of authors focusing on specific WHO regions entered their findings into the same template that included the following: (a) general context and background for the region covered; (b) key findings on prevalence estimates entered into the same format presented in [Tables I](#tblI){ref-type="table"}--[III](#tblIII){ref-type="table"}; (c) key findings clinical characterization summarized qualitatively; and (d) commentary on opportunities and barriers in conducting research in the region covered. Studies included were appraised by each group of authors who decided on inclusion and exclusion based on the criteria outlined earlier. M.E. reviewed all entries and combined the results, and together with E.F. performed overall appraisal of the data included. All authors subsequently verified the information in the final article. The diversity in the methodological approaches precluded the possibility of any further analysis of these estimates included meta-analysis but average figures and basic analyses were included in later sections.

Methodological Issues and Interpretation of Prevalence Estimates
================================================================

Before summarizing the key findings related to prevalence and clinical characterization, we will discuss some methodological issue that need to be accounted for when interpreting epidemiological data. These include characterization of PDD, changes in concepts over time, and case identification and evaluation.

Characterization of PDD
-----------------------

Over time, the definitions of autism have changed as illustrated by the numerous diagnostic criteria that were used in both epidemiological and clinical settings. Starting with the narrowly defined Kanner\'s autism, definitions progressively broadened in the criteria proposed by Rutter \[Rutter, [@b73]\], and then International Classification of Diseases (ICD)-9 \[WHO, [@b82]\], Diagnostic and Statistical Manual of Mental Disorders (DSM)-III \[American Psychiatric Association, [@b4]\] and DSM-III-R \[American Psychiatric Association, [@b5]\], and more recently in the two major nosographies used worldwide: ICD-10 \[WHO, [@b83]\] and DSM-IV \[American Psychiatric Association, [@b6]\]/DSM-IV-TR \[American Psychiatric Association, [@b7]\]. The first diagnostic criteria reflected the more qualitatively severe forms of the phenotype of autism, usually associated with severe delays in language and cognitive skills. It is only in the 1980s that less severe forms of autism were recognized, either as a qualifier for autism occurring without intellectual disability (so-called "high-functioning" autism), or as separate diagnostic categories (PDDs not otherwise specified \[PDDNOS\]) within a broader class of autism spectrum disorders (ASD) denominated "PDDs" (an equivalent to ASD) in current nosographies. Whilst it had been described in the literature as early as 1944, one type of PDD, Asperger disorder, appeared in official nosographies only in the 1990s and, then, with unclear validity, especially with respect to its differentiation from "high-functioning" autism. Subtypes of PDD that existed in DSM-III subsequently disappeared (i.e., autism---residual state). While there is generally high inter-rater reliability on the diagnosis of PDDs and commonality of concepts across experts, some differences persist between nomenclatures about the terminology and precise operationalized criteria of PDDs. For example, DSM-IV \[American Psychiatric Association, [@b6]\] has a broad category of PDDNOS, sometimes referred to loosely as "atypical autism," whereas ICD-10 \[WHO, [@b83]\] has several corresponding diagnoses for clinical presentations that fall short of AD, which include atypical autism (F84.1, a diagnostic category that existed already in ICD-9), Other PDD (F84.8), and PDD, unspecified (F84.9).

In the recent years, the research definitions of syndromes falling on the autism spectrum have been expanded further with an increasing reliance on a dimensionalization of the autism phenotype. As no impairment or diagnostic criteria are available for these milder forms, the resulting boundaries with the spectrum of PDDs are left uncertain. Whether or not this plays a role in more recent epidemiological studies is difficult to know, but the possibility should be considered in assessing results for the new generation of surveys. While the vast majority of studies have relied on these common nosographies, culturally specific instruments and systems have been used. For example, the Chinese Classification of Mental Disorders (CCMD) has been used in some of the studies appearing in Chinese journals and often combined with other classification systems.

Case Identification
-------------------

When an area or population has been identified for a survey, different strategies have been used to find participants matching the case definition retained for the study. Some studies have solely relied on existing service providers databases \[Croen, Grether, Hoogstrate, & Selvin, [@b23]\]; on special educational databases \[Fombonne, Zakarian, Bennett, Meng, & McLean-Heywood, [@b33]; Gurney et al., [@b41]; Lazoff, L., Piperni, & Fombonne, [@b54]\]; or on national registers \[Madsen et al., [@b60]\] for case identification. These studies have the common limitation of relying on a population group who happened to access the service provider or agencies rather than sampling from the population at large. As a result, participants with the disorder who are not in contact with these services are yet unidentified and not included as cases, leading to underestimation of prevalence proportion. This is a particularly significant issue when estimating prevalence using such methods in communities with recognized limitations in service provisions.

Other investigations have relied on a multistage approach to identify cases in underlying populations \[e.g., Baird et al. [@b10]; Kim et al., [@b51]\]. The aim of the first screening stage of these studies is to cast a wide net in order to identify participants possibly affected with a PDD, with the final diagnostic status being determined at a subsequent phase. The process used by researchers often consisted of sending letters or brief screening scales requesting school and health professionals and/or other data sources to identify possible cases of autism. Few investigations have relied on systematic sampling techniques that would ensure a near complete coverage of the target population. Moreover, each investigation differed in several key aspects of this screening stage. First, the thoroughness of the coverage of all relevant data sources varied enormously from one study to another. In addition, the surveyed areas were not comparable in terms of service development, reflecting the specific educational or health care systems of each country and of the period of investigation. Second, the type of information sent out to professionals invited to identify children varied from simple letters, including a few clinical descriptors of autism-related symptoms or diagnostic checklists rephrased in nontechnical terms, to more systematic screening strategy based on questionnaires or rating scales of known reliability and validity. Third, variable participation rates in the first screening stages provide another source of variation in the screening efficiency of surveys, although refusal rates tended, on average, to be very low.

Few studies provided an estimate of the reliability of the screening procedure. The sensitivity of the screening methodology is also difficult to gauge in autism surveys, and the proportion of children truly affected with the disorder but not identified in the screening stage (the "false negatives") remains generally unmeasured. The usual approach, which consists of sampling at random screened negative participants in order to estimate the proportion of false negatives, has not been used in these surveys for the obvious reason that, because of the relatively low frequency of the disorder, it would be both imprecise and very costly to undertake such estimations. This approach may gradually change in view of recent prevalence studies suggesting that autism can no longer be regarded as a rare condition. In any case, the magnitude of this of under- or over-estimation of prevalence studies relative to "true" prevalence is currently unknown.

Case Evaluation
---------------

When the screening phase is completed, participants identified as positive screens go through the next step involving a more in-depth diagnostic evaluation to confirm their case status. Similar considerations about the methodological variability across studies apply to these more intensive assessment phases. Participation rates in second stage assessments within the studies reviewed were generally high. The source of information used to determine caseness usually involved a combination of data coming from different informants and data sources (medical records, educational sources, parents, teachers, health professionals, etc.), with a direct assessment of the person with autism being offered in some but not all studies. Obviously, surveys of very large populations as those conducted in the United States by the CDC \[CDC, [@b18], [@b19], [@b20]\] or in national registers \[Madsen et al., [@b60]\] did not include a direct diagnostic assessment of all participants by the research team. However, these investigators could generally confirm the accuracy of their final caseness determination by undertaking, on a randomly selected subsample, a more complete diagnostic work-up. The CDC surveys have established a methodology for surveys of large populations that relies on screening of population using multiple data sources, a systematic review and scoring system for the data gathered in the screening phase combined with, in the less obvious cases, input from experienced clinicians. This methodology is adequate for large samples, and is likely to be used in the future for surveillance efforts. When participants are directly examined, the assessments were conducted with various diagnostic instruments, ranging from an unstructured examination by a clinical expert to the use of batteries of standardized measures by trained research staff. The Autism Diagnostic Interview \[ADI; Le Couteur et al., [@b55]\] and/or the Autism Diagnostic Observational Schedule \[ADOS; Lord et al., [@b57]\] have been increasingly used in the most recent surveys in North America and some European countries. Against this background and in view of these diverse methodological features in the studies we report, we now turn to the available evidence from epidemiological surveys and studies on clinical characterization.

Europe
======

Older Prevalence Estimates
--------------------------

Prior to the modern conceptualization of PDD, epidemiological surveys presented in [Table I](#tblI){ref-type="table"} conducted as early as the 1960s in Europe, mainly in Northern countries, provided useful information on rates of syndromes similar to autism but not meeting strict diagnostic criteria for AD then in use \[Fombonne, [@b30], [@b31]\]. At the time, different labels were used by authors to characterize these clinical pictures such as the triad of impairments involving deficits in reciprocal social interaction, communication, and imagination \[Wing & Gould, [@b89]\], or "autistic-like" syndromes \[Burd, Fisher, & Kerbeshan, [@b16]\]. These syndromes would be falling within our currently defined autistic spectrum, probably with diagnostic labels such as atypical autism and/or PDD-NOS. In surveys providing separate estimates of the prevalence of these developmental disorders, higher rates for the atypical forms were found compared with those for more narrowly defined AD \[see Fombonne, [@b29], p.172\]. This group received little attention in previous epidemiological studies and these participants were not counted in the numerators of prevalence calculations, thereby underestimating systematically the prevalence of what would be defined today as the spectrum of ADs. For example, in the surveys conducted by Lotter \[Lotter, [@b58]\] and Wing et al. \[Wing, Yeates, Brierly, & Gould, [@b90]\], prevalence figures would rise substantially if atypical forms had been included in the case definition. For purpose of historical comparisons, it is important to be attentive to this earlier figure, bearing in mind that the study was conducted in the early 1970s for the field work and that autism occurring in participants with an IQ within the normal range was not yet being investigated. Progressive recognition of the importance and relevance to autism of these less typical clinical presentations has led to changes in the design of more recent epidemiological surveys (see following discussion) that are now using case definitions that incorporate upfront these milder phenotypes.

Recent Prevalence Estimates
---------------------------

Available studies from Northern European countries (UK, Iceland, Denmark, Sweden) provide estimates for combined PDD as well as AD. Much less data are available from other European countries, namely from France, Germany, Portugal, and Israel. Sample sizes of multiple surveys estimating AD varied from 826 to 490 000 participants, with an age range of birth to adulthood. Prevalence rates varied from 1.9/10 000 to 72.6/10 000 with a median value of 10.0/10 000. In studies published since 1999, the median rate was 18.75/10 000. Studies providing estimate for combined PDD ranged in sample size from 2536 to 134 661 participants. All these surveys were published since 2000, and the majority since 2006. The diagnostic criteria reflect reliance on modern diagnostic schemes. There was high variation in prevalence proportions that ranged from a low 30.0/10 000 to a high of 116.1/10 000, with a median rate of 61.9/10 000.

The wide range of prevalence estimates reported in these studies may be attributed, at least in part, to methodological issues outlined earlier. Furthermore, such estimates should always be regarded in the context of the imperfect sensitivity of case ascertainment that results in downward biases in prevalence proportions. For example, in the Danish investigation \[Madsen et al., [@b60]\], case finding depended upon notification to a National Registry, a method that is usually associated with lower sensitivity for case finding. By contrast, case-finding techniques used in other surveys relied on multiple and repeated screening phases, involving both different informants at each phase and surveying the same cohorts at different ages, which certainly maximized the sensitivity of case identification \[Baird et al., [@b10]; Chakrabarti & Fombonne, [@b22]\].

Clinical Presentation
---------------------

Clinical characterization in Europe has increasingly relied on standardized measures, serving to reduce heterogeneity in clinical judgment. Assessments in several of the studies summarized earlier were often performed with these diagnostic measures that match the more dimensional approach for case definition. Extensive discussion of clinical presentation has been previously presented based on these studies \[Fombonne, [@b29], [@b31]\]. To summarize, males consistently outnumbered females in the vast majority of studies, with a ratio ranging from 1.33 to 16.0 for AD and 3.3 to 15.7 for PDD. In studies where IQ scores were available, the proportion of participants with normal IQ was 15.6--86.7% for AD and 45--85.3% for PDD. A few studies provided information on the social class of the families of autistic children. Of these, two older studies \[Brask, [@b15]; Lotter, [@b58]\] suggested an association between autism and social class or parental education. Studies conducted thereafter provided no evidence for the association. Thus, the epidemiological results suggest that the earlier findings were probably due to artifacts in the availability of services and in the case-finding methods, as already shown in other samples \[Schopler, Andrews, & Strupp, [@b75]; Wing, [@b87]\].

Some investigators have mentioned the possibility that rates of autism might be higher among immigrants in Northern Europe \[Gillberg, [@b37]; Gillberg, Schaumann, & Gillberg, [@b38]; Gillberg, Steffenburg, & Schaumann, [@b39]; Wing, [@b87]\]. A meta analysis including five studies found weak (nonsignificant) association between autism and mother\'s birthplace \[in the country where the study was conducted vs. abroad; Gardener, Spiegelman, & Buka, [@b34]\]. Serious methodological caveats related to these comparisons have been extensively discussed, including small samples, variation in rate of immigration in the areas samples, and the lack of a reasoned biologically plausible hypothesis linking immigration to autism \[Fombonne, [@b31]\].

Complex sociobiological \[Gillberg et al., [@b38]; Gillberg et al., [@b39]\] and environmental routes \[Dealberto, \#b[@b1001]\] have been suggested to explain the differences reported across a range of studies but none have been formally tested. In trying to ascertain factors that might explain differences in rates among immigrants and nonimmigrants, a recent study in the Netherlands \[Begeer, Bouk, Boussaid, Terwogt, & Koot, [@b12]\] showed that ethnic minorities were underrepresented among cases referred to autism institutions. Yet, the study also found that bias in clinical judgment among pediatricians may lead to under-referral. Moreover, the same bias was no longer apparent when pediatricians were asked to provide explicit structured ratings of the probability of autism. Taken together, in view of methodological limitations related to low numbers of identified cases, appropriateness of the comparison data that were used and large heterogeneity in the definition of immigrant status these findings cannot support a difference in PDD rates among immigrants and nonimmigrants.

Western Pacific, South East Asia, and the Eastern Mediterranean
===============================================================

Prevalence Estimates
--------------------

The oldest and most comprehensive prevalence surveys of AD in the Western Pacific Region come from Japan and China. While studies from Japan have tended to be published in English and have been reported in previous reviews, Chinese search engines provided a substantial body of studies published in local journals. Studies in this region had population size ranging from 3606 to 609 848. Since 2000, prevalence rates varied from 2.8/10 000 to 94/10 000 with a median value of 11.6/10 000. The median is somewhat similar (13/10 000) when older studies are included. The median value does not differ when older studies are excluded. This rate of AD is lower than current estimates from a comparable number of studies in Northern Europe but resembles estimates from older studies in that region. Only one estimate of AD was available from South East Asia. The study conducted in Indonesia estimated the rate of AD to be 11.7/10 000 \[Wignyosumarto, Mukhlas, & Shirataki, [@b85]\]. No estimates of AD were found in the Eastern Mediterranean.

In relation to combined PDD, three were available from the Western Pacific Region. One study in Australia estimated prevalence of PDD to be 39.2/10000 \[Icasiano, Hewson, Machet, Cooper, & Marshall, [@b44]\]. The highest rate of PDD internationally comes from a recent Korean study estimating the prevalence to be 189/10 000 \[Kim et al., [@b51]\] followed by a Japanese study estimating the prevalence to be 181.1/10 000 \[Kawamura, Takahashi, & Ishii, [@b48]\]. In fact, the former study \[Kim et al., [@b51]\] also reports a high probability estimate of 264/10 000 in addition to the general population estimate. By contrast, a study from China \[Wong & Hui, [@b91]\] reported a much lower estimate of 16.1/10 000. The Chinese study also reported that ASD incidence based on registry data in Hong Kong has been rather stable during 20 years. Estimated rates of 5-year incidence increased slightly from 5.19 (CI: 4.43--5.94) to 7.86 (CI: 6.68--9.05) per 10 000 over the study period.

Four estimate of PDD was available from South East Asia and the Eastern Mediterranean. These were 100/10 000 in Sri Lanka \[Perera, Wijewardena, & Aluthwelage, [@b70]\], 29/10 000 in the United Arab Emirates \[Eapen, Mabrouk, Zoubeidi, & Yunis, [@b26]\], 1.4/10 000 in Oman \[Al-Farsi et al., [@b2]\], and 6.3/10 000 in Iran \[Samadi, Mahmoodizadeh, & McConkey, [@b74]\]. Another estimate (not included in [Table II](#tblII){ref-type="table"}) from Iran \[1.9%, Ghanizadeh, [@b36]\] was available but the study did not confirm diagnosis in the identified group. In addition to these estimates, ASD incidence based on referral statistics in Bangkok were reported to have increased from 1.43 per 10 000 in 1998 to 6.94 per 10 000 in 2002 \[Plubrukarn, Piyasil, Moungnoi, Tanprasert, & Chutchawalitsakul, [@b71]\]. Factors related to broadening of the diagnostic concepts and increasing service seeking discussed earlier are likely to account for the variability in estimates as well as the observed increase. In this study, most of incidence changes stemmed from the increase of the AD cases, not from an increase of PDD-NOS. Additionally, incidence in children older than five did not change (1.52 to 1.66) during the same period \[Plubrukarn *et al*. [@b71]\]. These findings suggest that younger and more severe cases of PDD rather than older and milder cases of children over five years account for the increase. By contrast, the relatively low prevalence in the Omani and Iranian studies was attributed to prevalence caused by underdiagnosis and underreporting of cases resulting from limited access to service centers \[Al-Farsi et al., [@b2]\].

Clinical Presentation---Western Pacific
---------------------------------------

While detailed medical conditions and ASD phenotype data were not available, several studies reported similarities in the PDD phenotypes within this region. Excluding older studies from Japan, AD and PDD were more prevalent in boys than girls in the epidemiological studies in [Table II](#tblII){ref-type="table"}. In Japan, 66.4% of participants in the study with the highest prevalence estimate had IQ scores within the normal range. By contrast, all cases with AD identified in the population-based prevalence study in China had intellectual disabilities. Zhang and Ji, \[[@b93]\] speculated that autistic children with average cognitive function or mild intellectual disabilities might be neglected during the screening and case-ascertainment process. The Tanjin study \[Zhang & Ji, [@b93]\] reported that the AD prevalence was higher among urban children than children in suburban area (1.37% vs. 0.80%, respectively). Authors also noted that parents in urban areas had higher education and higher family income, leading to better accessibility for clinical care and rehabilitation services in these families.

Clinical Presentation---South East Asia
---------------------------------------

In addition to the two prevalence studies in [Table II](#tblII){ref-type="table"}, a few studies characterized relatively small samples of children in tertiary care settings in India among a larger literature on intellectual disabilities from the region. The studies had a high but variable male-to-female ratios \[Juneja, Mukherjee, & Sharma, [@b45]; Kalra, Seth, & Sapra, [@b46]; Malhi & Singhi, [@b62]; Singhi & Malhi, [@b78]\]. Across studies, the concern that most commonly led to referral from medical professionals was language delay or regression in language skills, followed by social difficulties and hyperactivity. Most children received the diagnosis of ASD between 3 and 6 years \[Juneja et al., [@b45]; Kalra et al., [@b46]\]. The time between recognition of symptoms by caregivers and diagnosis averaged about 2 years. Three Indian studies noted that the majority of families were from middle-class backgrounds \[Daley, [@b25]; Juneja et al., [@b45]; Singhi & Malhi, [@b78]\] and postulated that the higher socioeconomic families do not attend state-run facilities while the lower socioeconomic groups may not access care unless the child is acutely ill. Regression of skills was found in 25% of the children in one study \[Singhi & Malhi, [@b78]\]. Seizures were associated with ASD in 6.8--31% of children \[Daley, [@b25]; Juneja et al., [@b45]; Kalra et al., [@b46]\]. Intellectual disability was the most common co-morbid condition ranging from 24 to 95% of children. Perinatal events were examined in three studies \[Juneja et al., [@b45]; Kalra et al., [@b46]; Malhi & Singhi, [@b62]\]; two reported such events in up to 25% of the children whereas the third found no significant perinatal events.

Clinical Presentation---Eastern Mediterranean
---------------------------------------------

Similar to other regions, a number of studies report a high but variable male-to-female ratios \[Al-Farsi et al., [@b2]; Al-Salehi, Al-Hifthy, & Ghaziuddin, [@b3]; Eapen et al., [@b26]; Seif Eldin et al., [@b76]\]. The gender ratio in the Iranian study was more equally distributed between males and females \[Ghanizadeh, [@b36]\], but the rate reported in this study most likely reflects that of PDD symptoms among school-aged children rather than estimates of the disorder because a stage of diagnostic confirmation was not conducted \[Ghanizadeh, [@b36]\]. One study from Saudi Arabia reported that girls were older than boys in a tertiary referral center \[Al-Salehi et al., [@b3]\].

Parallel findings were observed across a number of studies from neighboring Arabic-speaking countries \[Al-Salehi et al., [@b3]; Eapen et al., [@b26]\], including one study that combined groups of children from nine countries \[Seif Eldin et al., [@b76]\]. These studies suggest high rates of behavioral, cognitive, and/or medical problems among children with PDD. One study highlighted that communication difficulties were a main reason for referral and reported a regressive profile in 10% of cases \[Al-Farsi et al., [@b2]; Al-Salehi et al., [@b3]\]. Two studies examining family characteristics of groups of children with PDD reported that the rate of consanguinity did not differ from a control group \[Seif Eldin et al., [@b76]\] or from population estimates \[Al-Salehi et al., [@b3]\]. Yet, the affected groups typically had higher parental age, incidence of pregnancy and labor complications \[Seif Eldin et al., [@b76]\], and incidence of familial mental health problems \[Eapen et al., [@b26]; Seif Eldin et al., [@b76]\]. In the Omani study, most cases identified were in the capital Muscat and the rates were variable across the other regions examined \[Al-Farsi et al., [@b2]\].

America
=======

Prevalence Estimates
--------------------

The vast majority of data from this region ([Table III](#tblIII){ref-type="table"}) comes from the United States and Canada from as early as the 1970s. The sample sizes of studies estimating AD were fairly large ranging from 8896 to 4 950 333 individuals. Estimates of AD varied from 0.7--40.5/10 000, with a median of 11/10 000. Studies done since 2000, however, yield estimates ranging from 11 to 50.5/10 000, with a median of 21.6/10 000. Studies estimating combined PDD, all of which were conducted since 2000 ranged from 8896 to 407 578 individuals in the target population. PDD estimates varied from 34 to 90/10 000, with a median of 65.5/10 000. Despite huge variation in ranges, both AD and PDD median estimates correspond closely to those derived from Northern Europe. Similar to the latter studies, a likely underestimation of the true population rates holds in this region as well. For example, the Atlanta survey by the CDC \[Yeargin-Allsopp et al., [@b92]\] was based on a very large population and included younger age groups than subsequent CDC surveys, and age specific rates were in fact in the 40--45/10 000 range in some birth cohorts \[Fombonne, [@b30]\].

Less data were available from other countries in America. Two published studies from Argentina \[Lejarraga et al., [@b56]\] and Venezuela \[Montiel-Nava & Peña, [@b65]\] along with unpublished reports from Brazil \[Paula, Ribeiro, Fombonne, & Mercadante, [@b69]\] and Mexico \[Marcín, personal communication\] provided prevalence data ([Table III](#tblIII){ref-type="table"}). There was also one study from the Caribbean (Aruba) \[van Balkom et al., [@b80]\]. All of the studies had relatively small sample sizes. The two studies from Venezuela and Aruba provided similar AD estimates of 13 and 19/10 000. With the exception of one study conducted in 1982, the remaining estimates of PDD ranged from 27 to 39.2/10 000. Administrative prevalence was available from Mexico through a registry of minors with disabilities reporting the number of children identified with autism, combined with Mexican census figures. Based on these figures the rate for childhood autism in Mexico was estimated to be 14.3 per 10 000 \[Marcín, personal communication\]. The estimates in those studies are smaller than those reviewed earlier but it is difficult to compare the findings given the limited data and methodological differences among studies.

Clinical Presentation
---------------------

Similar to Northern Europe, clinical characterization of PDD in the United States and Canada has increasingly relied on standardized measures and have been previously reviewed \[Fombonne, [@b29], [@b31]\]. Across all studies reported in [Table III](#tblIII){ref-type="table"}, the male-to-female ratio ranged from 2.2 to 5.8 for AD and from 2.7 to 6.7 for PDD. In studies reporting IQ scores, 23.8--62.5% of participants with AD and 31.8--60.0% of participants with PDD were reported to have normal IQ, with the higher estimate corresponding to the United States (South Carolina) and Aruba.

The largest studies internationally to utilize comparable methodology for examining variation of prevalence among neighboring geographical regions were conducted by the CDC in the United States. Findings from geographic regions falling within 10 American states found a threefold variation of rate by state, where Alabama had the lowest rate (3.3/1000) whereas New Jersey had the highest (10.6/1000) \[CDC, [@b19]\]. Subsequent CDC surveys found a similar variation of rates but the lowest was in Florida (4.2/1000) and highest in Missouri and Arizona (12.1/1000) \[CDC, [@b20]\]. The CDC surveys found that prevalence estimates were lower in sites that relied solely on health sources to identify cases compared with sites that also had access to education records, and hence a less rich database for those areas where ASD indicators could be found. As surveillance efforts continue, it is likely that awareness and services will develop in states that were lagging behind, resulting in a predictable increase in the average rate for the United States as time elapses.

CDC surveys also monitor variation in prevalence estimates among different ethnic communities. In the last survey \[CDC, [@b20]\] prevalence among white children was greater than that among black and Hispanic children. Similar to other world regions, service availability may account for the observed differences. In support of this, prevalence has increased over time across all sex, racial/ethnic, and cognitive functioning subgroups, making it unlikely that one group is differentially affected. Variability of estimates as a function of income level has also been noted. As an example, a study conducted in Texas showed that the top decile of income had a 6 times greater administrative prevalence than the bottom decile \[Palmer, Blanchard, Jean, & Mandell, [@b67]\].

Africa
======

Prevalence Estimates
--------------------

As early as 1970s, a report describing autism among children with mental handicaps who were known to authorities in six central and south African countries reported a preliminary observation that the number of cases of autism maybe smaller than those observed in the UK \[Lotter, [@b59]\]. Findings from this preliminary report, which was not designed as an epidemiological survey, were never corroborated. At the time, however, this served as crucial evidence that autism can be identified across varied geographic region. Similar to the conclusion of a recent review on autism in Africa \[Bakare & Munir, [@b11]\], we could not identify published data on population-based estimates of prevalence of PDD from African region.

Clinical Presentation
---------------------

A few studies \[reviewed in Ametepee & Chitiyo, [@b8]\] including Lotter\'s \[Lotter, [@b59]\], documented unambiguous recognition of autism among African children, albeit raising some questions about the relative frequency of some of the manifestations \[Lotter, [@b59]; Mankoski et al., [@b63]\]. A higher male-to-female ratio was consistent \[Khan & Hombarume, [@b49]; Lotter, [@b59]; Mankoski et al., [@b63]\]. Similar to observations from other regions, those studies suggested an over representation of higher socioeconomic background and higher frequency of cases with intellectual difficulties, i.e., the children identified were mainly nonverbal. Yet, none of the studies used appropriate tools for the evaluation of cognitive abilities and similar arguments related to service accessibility apply here as well. In one study, 3/14 cases described were described as having developed autism after the second year subsequent to a severe malaria infection \[Mankoski et al., [@b63]\]. The findings, however, were never replicated with appropriate sample sizes or with a prospective rather than retrospective methodology to account for the possibility of biased recall. In contrast to the dearth of evidence, there has been an abundance of claims regarding the prevalence and etiology of the autism in Africa \[reviewed in Ametepee & Chitiyo, [@b8]; Bakare & Munir, [@b11]\]. The clinical presentation of the condition in this region remains elusive.

PDD in the Global Context: Prevalence, Determinants, and Burden
===============================================================

Global Variation in Prevalence Estimates
----------------------------------------

Epidemiological surveys of autism and AD and PDD (summarized in[Figs 1](#fig01){ref-type="fig"} and [2](#fig02){ref-type="fig"}) have now been conducted in several countries. Methodological differences in case definition and case-finding procedures make between survey comparisons difficult to perform. However, most studies conducted since the year 2000 in different geographical regions and by different teams converge to estimates to a median of 17/10 000 for AD and 62/10 000 for all PDDs combined ([Table IV](#tblIV){ref-type="table"}). This is currently the best estimate for the prevalence of PDDs available. The estimate represents an average figure and there is substantial variability across studies.

![Prevalence of autistic disorder from [Tables I](#tblI){ref-type="table"} and [II](#tblII){ref-type="table"} (rate/10 000 and 95% confidence interval).](aur0005-0160-f1){#fig01}

![Prevalence of PDD from [Tables I](#tblI){ref-type="table"} and [II](#tblII){ref-type="table"} (rate/10 000 and 95% confidence interval).](aur0005-0160-f2){#fig02}

###### 

Summary of Prevalence Estimates of AD and PDD Across World Regions Since the Year 2000. Medians are not Presented When there were Too Few Estimates Available Within a Given Region

                          AD estimates   PDD estimates                                  
  ----------------------- -------------- --------------- -------- -------- ------------ --------
  Europe                  19             7--39           16       62       30--116      14
  America                 22             11--40          7        65       13--110      12
  Western Pacific         12             2.8--94         12       ---      ---          3
  South East Asia         ---            ---             1        ---      ---          1
  Eastern Mediterranean   ---            ---             0        ---      ---          3
  Africa                  ---            ---             0        ---      ---          0
  **All**                 **17**         **2.8--94**     **36**   **62**   **1--189**   **33**

AD, autistic disorder; PDD, developmental disorder.

Notwithstanding considerable variability across and within geographical regions, estimates of AD collected since the year 2000 in America, Western Pacific, and Europe do not differ statistically (*P* = 0.3). While considerably less studies have been conducted on PDD, those estimates do not differ between America and Europe. The global mean prevalence of 62/10 000 translates into one child out of 160 with a PDD. Some well-controlled studies have, however, reported rates that are two to three times higher \[Baird et al., [@b10]; Kawamura et al., [@b48]; Kim et al., [@b51]\]. By contrast, in many regions of the world including Africa, prevalence estimates are either unavailable or preliminary. Moreover, within each of the regions covered, the majority of studies were conducted in circumscribed regions, namely, in northern Europe, Japan, China, and the United States. With the exception of China, countries where a relatively large evidence base exists are high-income countries. A few studies have been conducted in middle-income countries and no prevalence estimates were available from any low-income country.

Our minimal criteria for inclusion of prevalence estimates described in the previous section were motivated by the need for a systematic and comprehensive account of available estimates. However, given the significant variability in resulting prevalence estimates, and the variability in methodological features outlined earlier, the estimates should be considered with caution. Specifically, these should not be considered as reflecting "world-wide" estimates, but rather, a general reflection of the current state of evidence from various regions. As we note in the final section, our findings offer critical public health messages regarding the need for scaling of services as well as research in most of the world\'s regions.

Phenotypic presentation of PDD
------------------------------

As early as the 1970s, the phenotypic characteristics of autism have been observed and described across a wide range of geographical, economic, social and cultural settings. Based on available evidence world-wide, the higher ratio in males relative to females is consistently observed. It is also clear that PDD is associated with a degree of intellectual impairment among a significant portion of those affected. Yet, the range of variation in gender ratio and intellectual functioning is vast. By contrast, very few studies examined the impact geographical, economic, social and cultural factors directly and, on the whole, the findings indicate little impact. Differences in such factors reported retrospectively in large-scale surveys such as those conducted by the CDC \[CDC, [@b18], [@b19]\] may be accounted for entirely by differences in service provisions, richness of registered data, and community awareness. Moreover, there is a striking absence of controlled studies examining the potential impact of such factors on the understanding, experience, expression, and help-seeking for autism, masking the true global burden of the condition. Some positive indicators suggest improved identification of autism in low-resource countries, as inferred from the increase in referrals and identified cases \[e.g., Plubrukarn et al., [@b71]\]. Yet, it has also been suggested that regional variation in parental education may still determine their help seeking for autism \[Seif Eldin et al., [@b76]\] and that it is predominantly severe cases that are currently being identified in poor communities \[Daley, [@b25]; Juneja et al., [@b45]; Singhi & Malhi, [@b78]\]. Such possibilities require confirmation in future large-scale controlled studies.

The data we reviewed is also relevant for the ongoing debate regarding time trends in autism. Considering all studies conducted since the 1960s, prevalence data suggest that there is a correlation between AD estimates and year of publication (*r* = 0.4, *P* \< 0.01, R^2^ = 18.5%). While this simple test is limited by the considerable variation, it does confirm that when data is considered from several world regions there is indeed a rise in prevalence over time, confirming previous conclusions. Such time trends have given rise to the hypothesis that there is a secular increase in rates of autism. However in view of a number of conceptual and methodological reasons, no inference related to trends in the incidence of PDDs can be derived from a simple comparison of prevalence rates over time. In particular, it is crucial to differentiate prevalence (the proportion of individuals in a population who suffer from a defined disorder at any one point in time) from incidence (the number of new cases occurring in a population over a period of time). Prevalence is useful to estimate needs and plan services; only incidence rates can be used for causal research. Both prevalence and incidence estimates will increase when case definition is broadened and case ascertainment is improved. Time trends in rates can therefore only be gauged in investigations that hold these parameters under strict control over time. Several factors accounting for this rise have been proposed and discussed extensively in previous studies. These factors include: (a) the broadening of diagnostic criteria; (b) the increased efficiency over time in case identification methods used in surveys as well as changes in diagnostic practices; and (c) the diagnostic substitution (or switching) when some diagnostic categories become increasingly familiar to health professionals and/or when access to better services is insured by using a new diagnostic category.

The Way Forward
===============

Prospects and Challenges in Global Epidemiological Research
-----------------------------------------------------------

Because significant costs are associated with prevalence studies, some have questioned whether country-specific estimates should be a priority, especially where resources are limited and priorities include preventable life-threatening conditions. Such epidemiological studies are useful, however, for assessing needs and priorities within each community. Epidemiological studies often provide systematic information regarding the availability, quality, and accessibility of existing services. These studies also require development of valid tools for systematic clinical characterization, including screening and/or diagnostic instruments that can be useful for immediate improvements in training, services, and awareness, as well as facilitating future research. As such, epidemiological research may be viewed as a systematic framework for unveiling local burden and informing policy and research.

The power of epidemiological research extends well beyond the communities in which it is conducted, particularly in view of mounting speculation regarding time trends and the potential impact of geographical and socioeconomic factors on the prevalence and possibly on the incidence of autism. While research within a global context is likely to help address such perplexing puzzles, currently, available evidence is extremely limited. There is also a clear need for better theoretical and experimental modelling to test the possible mechanisms through which various factors may have an impact on incidence, clinical presentation, or both. Studies using comparable methodology to estimate prevalence across different geographical regions and to monitor changes to it over time provide a powerful approach. Such findings may address whether certain factors, environmental or otherwise, operating in specific regions, have a disproportionate impact on prevalence over time as well as ascertain the true global burden of the condition. Moreover, epidemiological studies can be potentially translated into public health practices through developing or validating screening and diagnostic methods and though strengthening capacity for services.

Rapid developments in the public policy context for autism in various regions have given rise to promising opportunities for furthering research in this area. A number of parent and professional led groups as well as governmental agencies have been established around the world, who are actively working on creating awareness, services, and advocacy for people with PDD. While the critical need for population-based studies of the epidemiology of PDD may be evident, it is essential to also consider the likely reasons for the current lack of such data.

Funding for research in some countries is disproportionate to the burden of disease they face (referred to as the 10/90 gap, that is, only 10% of global spending on health research is directed towards the problems that primarily affect the poorest 90% of the world\'s population). There is limited local capacity to conduct research in these settings, let alone research in field of childhood autism. Despite this situation being common to several low- and middle-income countries, our review highlighted that regional or country-specific economic and development capacity only one factor contributing to the scarcity of data. More general contextual difficulties may be encountered in conducting epidemiological surveys worldwide. First, the epidemiological research concept of PDD is relatively new, thus little cumulative information on epidemiology of PDD are available. Second, service availability/accessibility in many regions remains low, which creates problems for case finding. Third, awareness of PDD among the public as well as clinical experts remains limited. Such contextual factors may help explain why epidemiological data is limited in some countries within Western Europe, where psychoanalytic frameworks for management of PDD may still be operative, as they were in the 1960s and 1970s in other regions of Europe and North America (and remain operative is some parts of Europe). Hence, there is a need for continued educational, training, and awareness programs with specific targets tailored to the needs and resources available for each community.

Further challenges face the research community in particular. Diagnosis of PDD still relies on behavioral observation, leaving room for wide variation in clinical judgment, and in cultural and social impact in the identification of biological conditions. While these challenges have been addressed in some countries with strong research capacity through the development and standardization of diagnostic tools, progress has been slow in using such instruments widely within those countries themselves, let alone, within a global context, where significant cultural and linguistic variation across and within communities needs to be accounted for. A number of instruments have been or are in the process of being translated and/or validated. Translation of instruments has also been identified as a priority within the International Epidemiology Network (<http://www.autismepidemiology.net>). Yet the biggest challenge to describing the true burden of PDD is the availability of low cost tools for epidemiological surveys, which would allow those to be conducted with adequate samples in different world regions.

Further questions are often raised as to whether research efforts need to focus on PDD in particular or incorporate a wider range of disabilities. For example, a group of scientists and practitioners, led by INCLEN-India (<http://www.inclentrust.org>), have been developing and validating a neurodevelopmental screening test for use by community health workers for the detection of 10 neurodevelopmental disabilities (including ASD). This work is leading to the emergence of a collaborative framework for research on neurodevelopmental disorders in the region to carry out multicenter epidemiological studies with a common protocol. The availability of these tools will provide a new opportunity for studies of the burden, determinants and needs of families affected by PDD in the region. Epidemiological studies themselves may also eventually provide revealing findings regarding the manifestation of PDD across cultures. In view of the increased awareness of autism worldwide and the interest from a wide range of stakeholders, research in this relatively narrow area may become a vehicle for broader improvements in evidence, and consequently in practice standards, in child mental health in general.

Public Health Implications
--------------------------

Based on already available knowledge indicating that PDDs are not limited to high-income countries; the need for services especially in low and middle-income countries is felt more than before. It is imperative to engage community resources and more peripheral extensions of health systems as well. The situation in low- and middle- income countries appears to be that child health programs focus mainly on child survival issues. Very little attention is paid to developmental disabilities at policy and implementation level and as a result budget allocations and human resource deployment is directed away from these programs. For example, some regions in Africa face a dual burden of communicable and noncommunicable conditions, including childhood disabilities \[Murray, Lopez, Mathers, & Stein, [@b66]\]. Dysfunctional health systems contribute further to lack of service delivery for children with developmental disabilities. Where they exist, access to these facilities is also hindered by lack of effective identification and referral programs. An even bigger barrier has been the lack of an evidence-based, affordable, package of care for people with PDD, which could be delivered if such facilities were available. Only recently WHO\'s mhGAP has included evidence-based and simple interventions for PPD and intellectual disability in a package that needs to be pilot tested and evaluated in low- and middle-income countries. This review indicates that increase in prevalence estimates over time most likely represent broadening of the diagnostic concepts, diagnostic switching from other developmental disabilities to PDD, service availability, and awareness of autistic spectrum disorders in both the lay and professional public. This has clear public health implications that services for different categories of developmental disorders should not be segregated prematurely and health systems need to consider overarching programmes to fill the gap for all developmental disorders.
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